<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Interdiscip Perspect Infect Dis</journal-id><journal-id journal-id-type="publisher-id">IPID</journal-id><journal-title>Interdisciplinary Perspectives on Infectious Diseases</journal-title><issn pub-type="ppub">1687-708X</issn><issn pub-type="epub">1687-7098</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19277100</article-id><article-id pub-id-type="pmc">2648624</article-id><article-id pub-id-type="doi">10.1155/2008/290769</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Probiotics and Gastrointestinal Infections</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Britton</surname><given-names>Robert A.</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Versalovic</surname><given-names>James</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI 48824, USA</aff><aff id="I2"><sup>2</sup>Departments of Pathology, Baylor College of Medicine and Texas Children's Hospital, 6621 Fannin Street, MC 1-2261, Houston, TX 77030, USA</aff><author-notes><corresp id="cor1">*Robert A. Britton: <email>rbritton@msu.edu</email></corresp><fn fn-type="other"><p>Recommended by Vincent B. Young</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>4</day><month>2</month><year>2009</year></pub-date><volume>2008</volume><elocation-id>290769</elocation-id><history><date date-type="received"><day>14</day><month>8</month><year>2008</year></date><date date-type="accepted"><day>27</day><month>10</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 R. A. Britton and J. Versalovic.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Gastrointestinal infections are a major cause of morbidity and mortality                   worldwide, particularly in developing countries. The use of probiotics to prevent and                   treat a variety of diarrheal diseases has gained favor in recent years. Examples where                   probiotics have positively impacted gastroenteritis will be highlighted. However, the overall                   efficacy of these treatments and the mechanisms by which probiotics ameliorate gastrointestinal                   infections are mostly unknown. We will discuss possible mechanisms by which probiotics could have a                   beneficial impact by enhancing the prevention or                   treatment of diarrheal diseases.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. INTRODUCTION</title><p>Within the microbiota, individualbacteria containing important genes may benefit the host in different ways. Asone considers the vast community of commensal microbes, subsets of theseorganisms may have important physiologic benefits for the host in the contextof human nutrition and host:microbe interactions. Probiotics may stimulateimmunity, regulate immune signaling pathways, produce antipathogenic factors,or induce the host to produce antipathogenic factors. Probiotics may producesecreted factors that stimulate or suppress cytokines and cell-mediatedimmunity. These factors may also interfere with key immune signaling pathwayssuch as the NF-<italic>&#x003ba;</italic>B and MAP kinase cascades. Probiotics may produce factors thatinhibit pathogens and other commensal bacteria, effectively enabling thesemicrobes to compete effectively for nutrients in complex communities. Microbesthat produce antipathogenic factors may represent sources of novel classes ofantimicrobial compounds, and these factors may be regulated by masterregulatory genes in particular classes of bacteria. Microbes can also regulatesignaling pathways in immune cells that result in the production ofantimicrobial factors by mammalian cells, effectively resulting in remodelingof intestinal communities and prevention or treatment of infections.</p><p>Gastrointestinalinfections are a major cause of morbidity and mortality worldwide. Studiesconducted in 2006 found that, globally, severe diarrhea and dehydration areresponsible each year for the death of 1,575,000 children under the age offive. This represents 15% of the 10.5 million deaths per year of children inthis age group [<xref ref-type="bibr" rid="B1">1</xref>]. According to recentestimates, acute gastroenteritis causes as many as 770,000 hospitalizations peryear in the United States [<xref ref-type="bibr" rid="B2">2</xref>]. Enteric pathogens includeviruses (rotaviruses, noroviruses) and bacteria such as different strains ofpathogenic <italic>Escherichia coli</italic>,toxigenic <italic>Clostridium difficile</italic>, <italic>Campylobacter jejuni</italic>, and <italic>Vibrio cholerae</italic>. Thesepathogens produce different types of toxins that can cause severe orlife-threatening dehydration and diarrhea. Despite medical advances indiagnosis and treatment, the percent and number of hospitalized pediatricpatients less than 5 years of age with severe rotavirus infection significantlyincreased when a recent time period (2001&#x02013;2003) was compared to an earliertime period (1993&#x02013;1995) [<xref ref-type="bibr" rid="B3">3</xref>]. In addition to the typicalpattern of acute gastroenteritis, infectious agents such as enteropathogenic <italic>E. coli</italic> (EPEC) may cause persistent,chronic diarrhea in children lasting longer than 1 week [<xref ref-type="bibr" rid="B4">4</xref>]. Such persistent infections may increase the risk of dehydrationand long-term morbidities. Importantly, the relative contributions of EPEC andother bacterial pathogens to disease remains controversial to some extent. A recent study highlighted that increased relative risk of gastrointestinal disease inchildren was only demonstrable for enteric viruses [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>Recent studies have highlightedlong-term morbidities associated with gastroenteritis. Early childhood diarrheapredisposes children to lasting disabilities, including impaired fitness,stunted growth, and impaired cognition and school performance [<xref ref-type="bibr" rid="B6">6</xref>]. Along with this data, new research on maternal and child undernutritionreported in <italic>The Lancet</italic> in January2008 links poor nutrition with an increased risk for enteric infections inchildren. Furthermore, irritable bowel syndrome (IBS), a costly and difficultto treat condition that affects 20% of the United States population [<xref ref-type="bibr" rid="B7">7</xref>], has medical costs of up to$30 billion per year, excluding prescription and over-the-counter drug costs [<xref ref-type="bibr" rid="B8">8</xref>]. IBS is precipitated by anepisode of acute gastroenteritis in up to 30% of all cases in prior studies [<xref ref-type="bibr" rid="B9">9</xref>]. Therefore, preventing ortreating acute gastroenteritis before long-term sequelae develop woulddrastically reduce hospitalizations, disability-adjusted life years, and bothdirect and indirect medical costs.</p><p>Accurate diagnosis of acutegastroenteritis is an ongoing challenge even in sophisticated academic medicalcenters. In a pediatric patient population exceeding 4,700 children, less than50% of stool samples that underwent complete microbiologic evaluation yielded aspecific diagnosis [<xref ref-type="bibr" rid="B10">10</xref>]. Enteric viruses represented the predominant etiologic agents in acute gastroenteritisin children less than 3 years of age, and bacteria caused the majority of casesof acute gastroenteritis in children older than 3 years of age [<xref ref-type="bibr" rid="B10">10</xref>]. The diagnostic challengeswith enteric viruses include the relative paucity of stool-based molecular orviral antigen tests and the inability to readily culture most enteric viruses. Bacterial pathogens may be difficult to identify (such as most strains ofdisease-causing <italic>E. coli</italic>) because of the lack of specific assaysfor these infections. The relative insensitivity of stool-based toxin assaysfor the detection of toxigenic <italic>C. difficile</italic> precludes accurate diagnosis. In a children's hospital setting,combination toxin antigen testing yielded sensitivity below 40% in pediatricpatients (J. Versalovic, unpublished data). The introduction of new molecularassays for real-time PCR detection of toxin genes directly in stool hasmarkedly improved the ability to diagnose antimicrobial-associated diarrhea andcolitis due to toxigenic <italic>C. difficile</italic> [<xref ref-type="bibr" rid="B11">11</xref>]. In addition,approximately 15&#x02013;25% of cases of antimicrobial-associated diarrhea are causedby <italic>C. difficile</italic>. The prevalence ofantimicrobial-associated diarrhea and gastrointestinal disease highlights theimportance of alternatives to antibiotic strategies for treatment. Furthermore,antibiotics have limited utility for the treatment of gastroenteritis ingeneral. Antimicrobial agents are not generally recommended as preventionstrategies because of the problems of antibiotic resistance andantimicrobial-associated disease. Thus, instead of suppressing bacterialpopulations with antibiotics, can probiotics be used to remodel or shift microbialcommunities to a healthy state [<xref ref-type="bibr" rid="B12">12</xref>]?</p></sec><sec sec-type="section" id="sec2"><title>2. PROBIOTICS</title><sec id="subsec2.1"><title>2.1. The need for mechanistic details ofprobiotic action</title><p>The useof probiotics to prevent and treat a wide variety of conditions has gainedfavor in the past decade. This is in part due to a need to find alternatives totraditional therapies such as antibiotics as well as the lack of goodtreatments for GI ailments. While there are increasing reports of the efficacyof probiotics in the treatment of diseases such as pouchitis [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>],diarrhea [<xref ref-type="bibr" rid="B15">15</xref>&#x02013;<xref ref-type="bibr" rid="B17">17</xref>],and irritable bowel syndrome [<xref ref-type="bibr" rid="B18">18</xref>], the scientific basis for theuse of probiotics is just beginning to be understood. We will focus on thepotential applications for probiotics in the treatment of diarrheal disease. Severalexamples will highlight how probiotics may be selected for and utilized againstpathogens causing gastroenteritis.</p><p>The concept of using probioticmicroorganisms to prevent and treat a variety of human ailments has been aroundfor more than 100 years [<xref ref-type="bibr" rid="B19">19</xref>]. With the rise in the number of multidrug resistant pathogens and therecognition of the role that the human microbiota plays in health and disease,a recent expansion in the interest in probiotics has been generated. Thisphenomenon is apparent in both the numbers of probiotic products being marketedto consumers as well as the increased amount of scientific research occurringin probiotics. Although many of the mechanisms by which probiotics benefithuman beings remain unclear, probiotic bacteria are being utilized morecommonly to treat specific diseases.</p><p>Several definitions of whatconstitutes a &#x0201c;probiotic&#x0201d; in the literature have been formulated. For thisreview, we use the definition derived in 2001 by the Food and AgriculturalOrganization (FAO) and the World Health Organization (WHO)&#x02014;&#x0201c;Probiotics arelive microorganisms which when administered in adequate amount confer a healthbenefit on the host.&#x0201d;  [<xref ref-type="bibr" rid="B20">20</xref>]. This definition is the currently accepted definition by the InternationalScientific Association for Probiotics and Prebiotics (ISAPP)(<ext-link ext-link-type="uri" xlink:href="http://www.isapp.net/">http://www.isapp.net/</ext-link>).</p></sec><sec id="subsec2.2"><title>2.2. Antipathogenic activities</title><p>Perhapsthe most important scientific question regarding the use of probiotics inmedicine is the identification of mechanisms by which probiotics impact humanhealth. Several mechanisms have been implicated but most have not beenexperimentally proven (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Here, we discuss possible mechanisms that arerelevant for the treatment of diarrheal diseases. We will highlight researchexamples that support these putative mechanisms whenever possible.</p></sec><sec id="subsec2.3"><title>2.3. Stimulation of host antimicrobial defenses</title><p>Many probiotics have been shown toproduce antipathogenic compounds ranging from small molecules to bioactiveantimicrobial peptides. Most of these studies have focused on the in vitrosusceptibility of pathogens to products secreted by probiotic bacteria. In mostcases, the ability of an antimicrobial compound secreted by a probioticorganism to inhibit the growth of a pathogen in vivo has not been demonstrated. Conceptually, an antimicrobial compound produced by an organism would need tobe produced at a high enough level and in the right location in the intestinaltract to exert a strong effect on a pathogen in vivo.</p><p>An elegant proof of principle fordirect action of a probiotic-produced antimicrobial against a pathogen wasrecently reported by Corr  et al. who demonstrated that production of the bacteriocinAbp118 by <italic>Lactobacillus salivarius</italic> wassufficient to protect mice from disease by infection with <italic>Listeria monocytogenes</italic> [<xref ref-type="bibr" rid="B21">21</xref>]. To prove the action of the bacteriocin was directly responsible for theprotection of the mice, they generated a <italic>L. salivarius</italic> strain that was unable to produce Abp118 and showed that thismutant was incapable of protecting against <italic>L. monocytogenes</italic> infection. Notably, they were able to express a gene thatconfers immunity to the Abp118 bacteriocin within <italic>L. monocytogenes</italic> and showed that this strain was now resistant tothe probiotic effect of <italic>L. salivarius</italic> withinthe mouse. This study provided clear evidence that a probiotic-derivedbacteriocin could function directly on a pathogen in vivo.</p></sec><sec id="subsec2.4"><title>2.4. Pathogen exclusion via indirect mechanisms</title><p>In addition toproducing antimicrobial compounds that act directly on pathogens, probioticsmay stimulate host antimicrobial defense pathways. The intestinal tract has anumber of mechanisms for resisting the effects of pathogens including theproduction of defensins [<xref ref-type="bibr" rid="B22">22</xref>]. Defensins are cationic antimicrobial peptides that are produced in a number ofcell types including Paneth cells in the crypts of the small intestine andintestinal epithelial cells. A deficiency in alpha-defensin production has beencorrelated with ileal Crohn's disease [<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>]. Tissuesamples from patients with Crohn's disease showed a lower level ofalpha-defensin production and extracts from these samples exhibited a reducedability to inhibit bacterial growth in vitro. Moreover, some pathogenicbacteria have evolved mechanisms to inhibit the production or mechanism ofaction of defensins (reviewed in [<xref ref-type="bibr" rid="B25">25</xref>]).</p><p>Probiotics may act to stimulatedefensin activity via at least two mechanisms. First, probiotics may stimulatethe synthesis of defensin expression. This has been demonstrated for human betadefensin 2 (hBD-2), whose expression is upregulated by the presence of severalprobiotic bacteria via the transcription factor NF-<italic>&#x003ba;</italic>B [<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>]. Theimplication is that probiotic strains with this capability would strengthenintestinal defenses by increasing defensin levels. This effect is also observedwith certain pathogenic bacteria and thus is not a specific property ofprobiotic bacteria. Second, many defensins are produced in a propeptide formthat must be activated via the action of proteases. One well-characterized exampleis the activation of the murine defensin cryptdin (an alpha-defensin that isproduced by Paneth cells) by the action of matrix metalloprotease 7 (MMP-7) [<xref ref-type="bibr" rid="B28">28</xref>]. Micedefective for MMP-7 are more susceptible to killing by <italic>Salmonella</italic>. Evidence indicates that bacteria can stimulate theproduction of MMP-7 in the intestine [<xref ref-type="bibr" rid="B29">29</xref>]. Thus,one mechanism in which probiotics could participate in activating defensins isby stimulating the production of MMPs in the intestinal tract. Alternatively,probiotics could produce proteases that themselves activate defensins in theintestinal lumen. Although there is no evidence yet to support this mechanism, asubset of lactobacilli and streptococci encode MMP-like proteins in theirgenomes (R. Britton, unpublished observation). These MMPs are not found in anyother bacteria and thus it will be interesting to determine what effect theyhave on host cell function.</p></sec><sec id="subsec2.5"><title>2.5. Immunomodulation</title><p>Rather than  directly inhibiting the growth orviability of the pathogen, probiotics may compete for an ecological niche or,otherwise, create conditions that are unfavorable for the pathogen to take holdin the intestinal tract. There are many possible mechanisms for how pathogenexclusion may take place. First, several probiotics have been demonstrated toalter the ability of pathogens to adhere to or invade colonic epithelial cellsin vitro, for example, see [<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>]. Second, probiotics could sequester essentialnutrients from invading pathogens and impair their colonization ability. Third,probiotics may alter the gene expression program of pathogens in such a way asto inhibit the expression of virulence functions [<xref ref-type="bibr" rid="B32">32</xref>]. Lastly, probiotics may create an unfavorable environment for pathogencolonization by altering pH, the mucus layer, and other factors in the localsurroundings. It is important to note that although many of these possibleeffects have been demonstrated invitro, the ability of probiotics to exclude pathogens in vivo remains tobe proven.</p></sec><sec id="subsec2.6"><title>2.6. Enhancing intestinal barrier function</title><p>Probiotics may have strain-dependent effects on the immune system. Differentstrains representing different <italic>Lactobacillus</italic> species demonstrated contrasting effects with respect to proinflammatorycytokine production by murine bone marrow-derived dendritic cells [<xref ref-type="bibr" rid="B33">33</xref>]. Specific probiotic strains counteracted the immunostimulatory effects of otherstrains so that probiotics have the potential to yield additive or antagonisticresults. Interestingly, in this study, the anti-inflammatory cytokine IL-10 wasmaintained at similar levels [<xref ref-type="bibr" rid="B31">31</xref>]. Different probiotic <italic>Lactobacillus</italic> strainsof the same species may also yield contrasting effects with respect toimmunomodulation. Human breast milk-derived <italic>Lactobacillusreuteri</italic> strains either stimulated the key proinflammatory cytokine, humantumor necrosis factor (TNF), or suppressed its production by human myeloidcells [<xref ref-type="bibr" rid="B34">34</xref>]. The mechanisms of action may be due, not surprisingly, to contrasting effectson key signaling pathways in mammalian cells. Probiotic strains such as <italic>Lactobacillus rhamnosus</italic> GG (LGG) mayactivate NF-<italic>&#x003ba;</italic>B and the signal transducer and activator of transcription (STAT)signaling pathways in human macrophages [<xref ref-type="bibr" rid="B35">35</xref>]. Incontrast, probiotic <italic>Lactobacillus</italic> strains may suppress NF-<italic>&#x003ba;</italic>Bsignaling [<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>] or MAP kinase-/c-Jun-mediated signaling [<xref ref-type="bibr" rid="B34">34</xref>]. Stimulation of key signaling pathways and enhancement of proinflammatorycytokine production may be important to &#x0201c;prime&#x0201d; the immune system for defenseagainst gastrointestinal infections. Conversely, suppression of immunesignaling may be an important mechanism to promote homeostasis and tolerance tomicrobial communities with many potential antigens, and these immunosuppressivefunctions may promote healing or resolution of infections.</p></sec><sec id="subsec2.7"><title>2.7. Why understanding mechanisms is important?</title><p>The disruption ofepithelial barrier function and loss of tight junction formation in theintestinal epithelium may contribute to pathophysiology and diarrheal symptomsobserved during infection with certain pathogens [<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>]. Loss oftight junctions can lead to increased paracellular transport that can result influid loss and pathogen invasion of the submucosa. Pathogens may secretefactors such as enterotoxins that may promote excessive apoptosis or necrosisof intestinal epithelial cells, thereby disrupting the intestinal barrier. Enteric pathogens may also cause effacing lesions at the mucosal surface due todirect adherence with intestinal epithelial cells (e.g., EPEC). In contrast,probiotics have been reported to promote tight junction formation andintestinal barrier function [<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B41">41</xref>]. Althoughthe mechanisms of promoting barrier integrity are not well understood,probiotics may counteract the disruption of the intestinal epithelial barrierdespite the presence of pathogens. Probiotics may also suppress toxinproduction or interfere with the abilities of specific pathogens to adheredirectly to the intestinal surface. As a result, pathogens may have adiminished ability to disrupt intestinal barrier function.</p></sec><sec id="subsec2.8"><title>2.8. Important considerations for the use of probiotics:strain selection and microbial physiology</title><p>An importantchallenge in the field of probiotics is the identification of genes andmechanisms responsible for the beneficial functions exerted by these microbes. Successful identification of mechanistic details for how probiotics functionwill have at least three important benefits. First, understanding mechanisms ofaction will provide a scientific basis for the beneficial effects provided byspecific microbes. These breakthrough investigations will help move probioticsfrom the status of dietary supplements to therapeutics. Second, understandingmechanisms of probiosis and the gene products produced by probiotics will allowfor the identification of more potent probiotics or the development ofbioengineered therapeutics. As an example, the anti-inflammatory cytokine IL-10was postulated to be a potential therapeutic for the treatment of inflammatorybowel disease. To test this hypothesis, a strain of <italic>Lactococcus lactis</italic> engineered to produce and secrete IL-10 wasconstructed and demonstrated to reduce colitis in a murine model [<xref ref-type="bibr" rid="B42">42</xref>]. Early clinical trials in patients with inflammatory bowel disease indicate somerelief from symptoms when treated with the IL-10 overproducing strain. Third,the identification of gene products that are responsible for amelioratingdisease will allow researchers, industry, and clinicians to follow the productionof these products as important biomarkers during probiotic preparation. Asdiscussed below, the physiological state of microbes can be crucial to thefunctions of probiotics. Thus, it will be important to be able to follow theproduction of important bioactive molecules when culturing and processingprobiotics for applications in animals and humans.</p></sec><sec id="subsec2.9"><title>2.9. Probiotics and diarrhea</title><p>Probioticsare considered to be living or viable microorganisms by definition. Unlikesmall molecules that are stable entities, probiotics are dynamic microorganismsand will change gene expression patterns when exposed to differentenvironmental conditions. This reality has two important implications for thosewho choose to use these organisms to combat human or animal diseases. First,probiosis is a strain-specific phenomenon. As defining a bacterial species ischallenging in this age of full genome sequencing, it is clear that probioticeffects observed in vitro and in vivo arestrain specific. For example, modulation of TNF production by strains of <italic>Lactobacillus reuteri</italic> identified strainsthat were immunostimulatory, immunoneutral, and immunosuppressive for TNFproduction [<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B43">43</xref>]. These findings highlight the strain-specific nature of probiotic effectsexerted by bacteria. Thus, it is important for research groups and industry tobe cautious with strain handling and tracking so that inclusion of correctstrains is verified prior to administration in clinical trials.</p><p>The second key point is that thephysiology of the probiotic strain is an important consideration. Being livemicroorganisms, the proteins and secondary metabolites that are being producedwill change depending on growth phase. This feature raises a number ofimportant issues for the stability and efficacy of probiotic strains. First,probiotics are subjected to numerous environmental stresses during productionand after ingestion by the host. Most notably, probiotics used to treatintestinal ailments or whose mode of action is thought to be exerted in theintestinal tract must be able to survive both acid and bile stress duringtransit through the gut. The physiological state of the microbe is an importantcharacteristic that determines whether cells will be susceptible to differenttypes of environmental stress [<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>]. Forexample, exponentially growing cells of <italic>L. reuteri</italic> are much more susceptible to killing by bile salts than cells instationary phase [<xref ref-type="bibr" rid="B45">45</xref>]. Thus, it is important to consider the physiological state of the cells in termsof stress adaptation not only for survival in the host but also duringproduction. Second, the expression of bioactive molecules, which are most oftenresponsible for the health benefits exerted by probiotics, is often growth phase-dependent. For example, our groups have been investigating the production ofimmunomodulatory compounds and antimicrobial agents by strains of <italic>L. reuteri</italic>. In both cases, thesecompounds are more highly expressed in the entry into and during stationaryphase (unpublished observation).</p></sec></sec><sec sec-type="section" id="sec3"><title>3. PROBIOTICS AND THE PREVENTION ANDTREATMENT OF GASTROENTERITIS&#x02014;EXAMPLES</title><p>Commensal-derived probioticbacteria have been implicated as therapy for a range of digestive diseases,including antibiotic-associated colitis, <italic>Helicobacterpylori</italic> gastritis, and traveler's diarrhea [<xref ref-type="bibr" rid="B46">46</xref>]. Probiotic formulations may include single strains or combinations ofstrains. <italic>L. reuteri</italic> is indigenous to thehuman gastrointestinal tract, is widely present in mammals, and has never beenshown to cause disease. Inhuman trials, probiotic treatment with <italic>L. reuteri</italic> in small children with rotaviral gastroenteritis reduced theduration of disease and facilitated patient recovery [<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>], while in another study, it preventeddiarrhea in infants [<xref ref-type="bibr" rid="B17">17</xref>]. Despite the promising data from clinical trials, the primary molecularmechanisms underlying the antipathogenic properties of <italic>L. reuteri</italic> remain unknown.</p><p>Probiotics may be effective for theprevention or treatment of infectious gastroenteritis. In the context ofdisease prevention, several studies with different probiotic strains havedocumented that these bacteria may reduce the incidence of acute diarrhea by 15&#x02013;75%depending on the study [<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B47">47</xref>&#x02013;<xref ref-type="bibr" rid="B50">50</xref>]. Althoughthe relative impacts on disease incidence vary depending on the specificprobiotic strain and patient population, consistent benefits for diseaseprevention have been demonstrated in multiple clinical studies. In one diseaseprevention study [<xref ref-type="bibr" rid="B49">49</xref>],supplementation with <italic>Bifidobacteriumlactis</italic> significantly reduced the incidence of acute diarrhea and rotavirusshedding in infants. Studies that examined potential benefits of probiotics forpreventing antimicrobial-associated diarrhea have yielded mixed results [<xref ref-type="bibr" rid="B51">51</xref>&#x02013;<xref ref-type="bibr" rid="B54">54</xref>]. Oneprevention study reported a reduction in incidence of antimicrobial-associateddiarrhea in infants by 48% [<xref ref-type="bibr" rid="B52">52</xref>].</p><p>Probiotics may also be incorporated intreatment regimens for infectious gastroenteritis. Several meta-analyses ofnumerous clinical trials with different probiotics documented reductions indisease course of gastroenteritis that ranged from 17 to 30 hours [<xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B55">55</xref>]. Examinedanother way, meta-analyses of probiotics used in clinical trials ofgastroenteritis noted significant reductions of incidence of diarrhea lastinglonger than 3 days (prolonged diarrhea). The incidence of prolonged diarrheawas diminished by 30% or 60%, respectively, depending on the study [<xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B56">56</xref>] (summarizedin [<xref ref-type="bibr" rid="B55">55</xref>]). The probiotic agent, LGG, contributedto a significant reduction in rotavirus diarrhea by 3 days of treatment whenadministered to children as part of oral rehydration therapy [<xref ref-type="bibr" rid="B57">57</xref>]. Recent data compilations of a large series of probiotics trials by the CochraneDatabase of Systematic Reviews (<ext-link ext-link-type="uri" xlink:href="http://www.cochrane.org/">http://www.cochrane.org/</ext-link>) have yielded promising conclusions. As of 2008,probiotics appear to be effective for preventing acute gastroenteritis inchildren and may reduce duration of acute disease. Additionally, probiotics arepromising agents for preventing and treating antimicrobial-associated diarrhea,although intention-to-treat analyses have not demonstrated benefits.</p><sec id="subsec3.1"><title>3.1. Clostridium difficile andantibiotic-associated diarrhea</title><p>In what follows, wehighlight some possible mechanisms by which probiotics can be used toameliorate gastroenteritis. Because a number of infectious agents causediarrhea, colitis, and gastroenteritis, we will only focus on a few exampleswith the idea that many of the mechanisms discussed can be extended to otherbacterial or viral causes of diarrhea.</p><sec id="subsubsec3.1.1"><title>3.1.1. The potential role of probiotics in treating CDAD</title><p>Anestimated 500,000&#x02013;3,000,000 cases of <italic>Clostridiumdifficile-</italic>associated diarrhea (CDAD) occur annually with related healthcare costs exceeding $1 billion per year [<xref ref-type="bibr" rid="B58">58</xref>&#x02013;<xref ref-type="bibr" rid="B60">60</xref>]. CDAD occurs primarily in patients that have undergoneantibiotic therapy in a health care setting, indicating that alterations in theintestinal microbiota are important for the initiation of CDAD. In a small butincreasing number of cases, more severe complications will occur includingpseudomembranous colitis and toxic megacolon. Moreover, the emergence of metronidazole-resistantstrains of <italic>C. difficile</italic> hasdiminished the efficacy of metronidazole, and vancomycin- andmetronidazole-induced cecitis reinforces the need for new therapies for thetreatment and prevention of CDAD [<xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B62">62</xref>].</p><p>Approximately10&#x02013;40% of patients treated for an initial bout of CDAD will show recurrentdisease, often with multiple episodes [<xref ref-type="bibr" rid="B63">63</xref>]. Such recurrences are often refractory to existingtherapies including antibiotic therapy. Patients with recurrent CDAD had amarked decrease in the diversity of organisms in their fecal microbiota whilepatients that were free of recurrent disease had a normal microbiota [<xref ref-type="bibr" rid="B64">64</xref>]. Thus, therapies that restore a normal microbiota orsuppress <italic>C. difficile</italic> growth whileallowing the repopulation of the intestine with a favorable microbiota may beimportant to resolve infections and maintain intestinal health.</p></sec><sec id="subsubsec3.1.2"><title>3.1.2. Eradication of <italic>C. difficile</italic> through the production ofantimicrobial compounds</title><p>Probiotic organisms have been used to treat recurrent <italic>C. difficile</italic> in the past and in a fewcases have showed a modest effect in ameliorating recurrent disease [<xref ref-type="bibr" rid="B63">63</xref>]. This application has been somewhat controversial and atthis time the use of probiotics in ameliorating CDAD is not recommended [<xref ref-type="bibr" rid="B65">65</xref>]. However, the organisms tested were not specificallyisolated for the treatment of CDAD and, therefore, may have not been theappropriate strains to be used to prevent recurrent CDAD. In what follows, weoutline potential mechanisms in which carefully selected or engineeredprobiotics could be used in the treatment of <italic>C. difficile</italic> and the eradication of this pathogen.</p></sec><sec id="subsubsec3.1.3"><title>3.1.3. Competitive exclusion of <italic>C. difficile</italic>using probiotics</title><p>CDAD is currently treated by the useof antimicrobial agents that are effective against <italic>C. difficile</italic>, most often vancomycin or metranidazole. Because thesedrugs are broad-spectrum antibiotics, they likely play a role in recurrentdisease by suppressing the normal intestinal microbiota. Using antimicrobialcompounds that target <italic>C. difficile</italic> whileallowing restoration of resident organisms would be one possible mechanism toprevent recurrent CDAD.</p></sec><sec id="subsubsec3.1.4"><title>3.1.4. Probiotics and <italic>C. difficile</italic> spore germination</title><p>As mentioned above, CDAD is usually aninfection that is acquired in the hospital or other health care setting.</p><p>Therefore, aprobiotic that could competitively exclude <italic>C. difficile</italic> could be administered prior to entry into the hospital. Unfortunately, little is known about how and where <italic>C. difficile</italic> colonizes the intestine. Once this information isknown, strategies for blocking colonization with probiotics can be developed.</p><p>Nonetheless, a promising probioticapproach using non-toxigenic <italic>C. difficile</italic> has been described. Using a hamster model of <italic>C. difficile</italic> infection, Gerding et al. demonstrated a protectiveeffect of populating the hamster with strains of <italic>C. difficile</italic> that are unable to produce toxin prior to challengewith a virulent toxin-producing strain [<xref ref-type="bibr" rid="B66">66</xref>]. Colonization of the intestinal tract by the nontoxigenic strain appeared to berequired for protection. Currently, this probiotic approach is underinvestigation for use in humans (<ext-link ext-link-type="uri" xlink:href="http://www.viropharma.com/">http://www.viropharma.com/</ext-link>).</p></sec></sec><sec id="subsec3.2"><title>3.2. Enterohemorrhagic <italic>E. coli</italic></title><p>A likelycontributor to the difficulty in eradicating <italic>C. difficile</italic> from the intestine is the ability of the organism to developstress-resistant spores. The identification of probiotic strains that canprevent either spore formation or the germination of spores in the intestinaltract provides a promising avenue to combat CDAD. Recent work on sporegermination has provided in vitro assays in which inhibitory activitiesof probiotics can be tested [<xref ref-type="bibr" rid="B67">67</xref>].</p><p>Germination of spores in the laboratory requires the presence ofbile acids, with taurocholate and cholate demonstrating the best activity [<xref ref-type="bibr" rid="B67">67</xref>]. Thus, bile acids could play a role in signaling to <italic>C. difficile</italic> that spores are in the correct location of the gut togerminate. Sorg and Sonenshein have recently proposed a mechanism by which thereduction in the intestinal microbiota could lead to efficient sporegermination and overgrowth of <italic>C. difficile</italic> [<xref ref-type="bibr" rid="B67">67</xref>]. They found that the bile acid deoxycholate (DOC) was able to induce sporegermination but that subsequent growth was inhibited due to toxic effects ofDOC on vegetative <italic>C. difficile</italic>. Theirwork suggests a model in which a reduction in the concentration of DOC in theintestine, due to the disruption of the normal microbiota, removes this keyinhibitor of <italic>C. difficile</italic> growth. DOCis a secondary bile acid produced from dehydroxylation of cholate by the enzyme7<italic>&#x003b1;</italic>-dehydroxylase, an activity that is produced by members of the intestinalmicrobiota. While it is unclear whether or not antibiotic therapy reduces thelevel of DOC in the intestine, it is tempting to speculate that providingprobiotic bacteria capable of producing 7<italic>&#x003b1;</italic>-dehydroxylase may prevent intestinalovergrowth by <italic>C. difficile</italic> while thenormal microbiota is being reestablished.</p><sec id="subsubsec3.2.1"><title>3.2.1. Toxin sequestration and removal</title><p>Enterohemorrhagic <italic>E. coli</italic> (EHEC) infections cause sporadicoutbreaks of hemorrhagic colitis throughout the world (&#x0223c;100,000 cases per yearin the United States) [<xref ref-type="bibr" rid="B68">68</xref>]. Most infections result in the development of bloody diarrhea but a subset(&#x0223c;5&#x02013;10%) of EHEC patients (mostly children) will develop the life-threateningcondition hemolytic uremic syndrome (HUS) [<xref ref-type="bibr" rid="B69">69</xref>, <xref ref-type="bibr" rid="B70">70</xref>]. HUS is the leading cause of kidney failure in children. EHEC, which likelyevolved from an EPEC strain [<xref ref-type="bibr" rid="B71">71</xref>],also produces attaching and effacing lesions on host epithelial cells andreduces intestinal epithelial barrier function. In addition, EHEC strains arecharacterized by the expression of Shiga toxin (Stx) genes, and thus they canbe labeled as Shiga-toxin-producing <italic>E. coli</italic> (STEC). Currently, only supportive therapy for EHEC infection isavailable since antibiotic therapy may increase the risk of developing HUS,and therefore, novel therapies must be developed. One promising alternativetherapeutic may be the use of probiotics to treat EHEC infections.</p></sec><sec id="subsubsec3.2.2"><title>3.2.2. Inhibition of toxin production byEHEC&#x02014;identification of strains thatrepress the lytic functions of lambda</title><p>Shiga toxins areribosome-inactivating proteins that inhibit protein synthesis by removing aspecific adenine residue from the 28S rRNA of the large ribosomal subunit [<xref ref-type="bibr" rid="B72">72</xref>]. Shiga toxin is required for the development of HUS and recent work hasindicated that EHEC strains mutated for Shiga toxin production fail to causedisease in a germfree mouse model [<xref ref-type="bibr" rid="B73">73</xref>]. Indeed, injection of Shiga toxin with LPS directly into mice is sufficient togenerate a HUS-like disease in the kidneys of mice [<xref ref-type="bibr" rid="B74">74</xref>]. Therefore, Shiga toxin is an important mediator of HUS and therapies aimed atneutralizing its activity are expected to reduce or eliminate this life-threateningcomplication although current attempts at Shiga toxin neutralization have beenunsuccessful [<xref ref-type="bibr" rid="B75">75</xref>].</p><p>As a possible mechanism for treatingEHEC disease and reducing the incidence of HUS cases, Paton et al. havegenerated &#x0201c;designer probiotics&#x0201d; in which the oligosaccharide receptor (Gb<sub>3</sub>) for Stx is expressed on the cell surface ofan <italic>E. coli</italic> strain [<xref ref-type="bibr" rid="B76">76</xref>&#x02013;<xref ref-type="bibr" rid="B78">78</xref>]. Thisprobiotic strain was shown to be capable of neutralizing Stx in vitro. As aproof-of-concept, mice that were challenged with a STEC strain were protectedby administration of the probiotic expressing the Gb<sub>3</sub>  receptor  [<xref ref-type="bibr" rid="B79">79</xref>]. The protective effect was observed even when the strains were formalin-killedprior to use, supporting the hypothesis that toxin sequestration and removalwas the mechanism by which the mice were protected. Similar results have beenobtained using bacteria-expressing receptors for toxins produced by otherdiarrheal pathogens including enterotoxigenic <italic>E. coli</italic> (most common cause of traveler's diarrhea) and <italic>Vibrio cholerae</italic>.</p></sec><sec id="subsubsec3.2.3"><title>3.2.3. Inhibition of pathogen adherence and strengtheningof intestinal barrier functions</title><p>Stx genes are carried on lambdoid prophages and are usuallylocated in a late transcribed region of the virus, near the lytic genes [<xref ref-type="bibr" rid="B80">80</xref>]. Since no mechanism for toxin secretion has been identified, the location of Stxnear the lytic genes suggeststhat phage activation and cell lysis are responsible for Stx production andrelease. This genetic juxtaposition suggests that therapeutics that suppressthe lytic decision of lambda in vivo would greatly reduce or eliminate complicationscaused by systemic release of Stx.</p></sec></sec><sec id="subsec3.3"><title>3.3. Rotavirus</title><p>A keyinteraction of EHEC, as well as EPEC, with the intestinal epithelium is theformation of attaching and effacing lesions on the surface of the epithelium [<xref ref-type="bibr" rid="B81">81</xref>]. This interaction is brought about by factors secreted directly from the bacteriuminto the host cell, where a redistribution of the actin cytoskeleton occurs. EHEC and EPEC infection also induces a loss of tight junction formation andreduction of the intestinal epithelial barrier by inducing the rearrangement ofkey tight junction proteins including occludin [<xref ref-type="bibr" rid="B82">82</xref>, <xref ref-type="bibr" rid="B83">83</xref>]. Therapies that would either disrupt this interaction of EHEC/EPEC with theintestinal epithelium or inhibit the loss of barrier function should amelioratedisease.</p><p>Probiotics have shown some successinhibiting adhesion, A/E lesion formation and enhancing barrier function inresponse to EHEC infection in vitro. Johnson-Henry et al. tested the ability of <italic>Lactobacillusrhamnosus</italic> GG to prevent loss of barrier integrity and formation of A/Elesions induced by EHEC infection of cell culture in vitro [<xref ref-type="bibr" rid="B40">40</xref>]. They found that pretreatment of intestinal epithelial cells in vitro with LGGwas sufficient to reduce the number of A/E lesions and to prevent loss ofbarrier function as measured by transepithelial resistance, localization oftight junction proteins, and barrier permeability assays. Importantly, live LGGwas required for these effects as heat-killed bacteria were not effective inpreventing EHEC effects on epithelial cells.</p><p>Enteric viruses including norovirusesand rotavirus represent major causes of gastroenteritis, especially in youngchildren. Rotavirus infection results in acute gastroenteritis withaccompanying dehydration and vomiting mainly in children 3&#x02013;24 months of age. Human rotavirus primarily infects intestinal epithelial cells of the distal smallintestine, resulting in enterotoxin-mediated damage to intestinal barrierfunction. Recent studies indicate that probiotics may reduce the duration andameliorate disease due to rotavirus infection ([<xref ref-type="bibr" rid="B84">84</xref>];G. Preidis and J. Versalovic, unpublished data). Probiotics promoted intestinalimmunoglobulin production and appeared to reduce the severity of intestinallesions due to rotavirus infection in a mouse model. These findings and relatedinvestigations suggest that probiotics may diminish the severity and durationof gastrointestinal infections by mechanisms independent of direct pathogenantagonism. Probiotics may also promote healing and homeostasis by modulatingcytokine production and facilitating intestinal barrier function.</p></sec></sec><sec sec-type="section" id="sec4"><title>4. CONCLUDING REMARKS</title><p>Probiotics may provide an importantstrategy for the prevention and treatment of gastrointestinal infections. Specific bacteria derived from human microbial communities may have keyfeatures that establish these microbes as primary candidates for probiotictherapies. These beneficial microbes may have different effects within the hostsuch as prevention of pathogen proliferation and function. Probiotics may alsostimulate the host's immune function and mucosal barrier integrity. By workingvia different mechanisms of probiosis, probiotics may yield effects atdifferent steps in the process. Probiotics may prevent disease from occurringwhen administered prophylactically. Probiotics may also suppress or diminishseverity or duration of disease in the context of treatment. As our knowledgeof the human microbiome advances, rational selection of probiotics based onknown mechanisms of action and mechanisms of disease will facilitateoptimization of strategies in therapeutic microbiology. Ultimately, we expect thatprobiotics will help to promote stable, diverse, and beneficial microbialcommunities that enhance human health and prevent disease.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>Research in the Britton laboratory is supported by a grant fromthe Gerber Foundation, the Michigan State University Center for MicrobialPathogenesis, the Michigan State University Center for Renewable OrganicResources, and the Microbiology Research Unit at Michigan State under contractby the National Institutes of Health (NIH N01-AI-30058). J. Versalovic is supported by funding from the NIH (NIDDK R01 DK065075; NCCAM R21 AT003482; NCCAM R01 AT004326; NIDDK P30 DK56338, which funds the Texas Medical Center Digestive Diseases Center), the Office of Naval Research, and the Defense Advanced Research Projects Agency (DARPA).</p></ack><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>AD</given-names></name><name><surname>Mathers</surname><given-names>CD</given-names></name><name><surname>Ezzati</surname><given-names>M</given-names></name><name><surname>Jamison</surname><given-names>DT</given-names></name><name><surname>Murray</surname><given-names>CJ</given-names></name></person-group><article-title>Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data</article-title><source><italic>The Lancet</italic></source><year>2006</year><volume>367</volume><issue>9524</issue><fpage>1747</fpage><lpage>1757</lpage></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozak</surname><given-names>LJ</given-names></name><name><surname>Owings</surname><given-names>MF</given-names></name><name><surname>Hall</surname><given-names>MJ</given-names></name></person-group><article-title>National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data</article-title><source><italic>Vital and Health Statistics. Series 13</italic></source><year>2005</year><issue>158</issue><fpage>1</fpage><lpage>199</lpage></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>TK</given-names></name><name><surname>Viboud</surname><given-names>C</given-names></name><name><surname>Parashar</surname><given-names>U</given-names></name><etal/></person-group><article-title>Hospitalizations and deaths from diarrhea and rotavirus among children &#x0003c;5 years of age in the United States, 1993&#x02013;2003</article-title><source><italic>The Journal of Infectious Diseases</italic></source><year>2007</year><volume>195</volume><issue>8</issue><fpage>1117</fpage><lpage>1125</lpage><pub-id pub-id-type="pmid">17357047</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>RN</given-names></name><name><surname>Taylor</surname><given-names>LS</given-names></name><name><surname>Tauschek</surname><given-names>M</given-names></name><name><surname>Robins-Browne</surname><given-names>RM</given-names></name></person-group><article-title>Atypical enteropathogenic <italic>Escherichia coli</italic> infection and prolonged diarrhea in children</article-title><source><italic>Emerging Infectious Diseases</italic></source><year>2006</year><volume>12</volume><issue>4</issue><fpage>597</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">16704807</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vernacchio</surname><given-names>L</given-names></name><name><surname>Vezina</surname><given-names>RM</given-names></name><name><surname>Mitchell</surname><given-names>AA</given-names></name><name><surname>Lesko</surname><given-names>SM</given-names></name><name><surname>Plaut</surname><given-names>AG</given-names></name><name><surname>Acheson</surname><given-names>DWK</given-names></name></person-group><article-title>Diarrhea in American infants and young children in the community setting: incidence, clinical presentation and microbiology</article-title><source><italic>Pediatric Infectious Disease Journal</italic></source><year>2006</year><volume>25</volume><issue>1</issue><fpage>2</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16395094</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guerrant</surname><given-names>RL</given-names></name><name><surname>Kosek</surname><given-names>M</given-names></name><name><surname>Moore</surname><given-names>S</given-names></name><name><surname>Lorntz</surname><given-names>B</given-names></name><name><surname>Brantley</surname><given-names>R</given-names></name><name><surname>Lima</surname><given-names>AAM</given-names></name></person-group><article-title>Magnitude and impact of diarrheal diseases</article-title><source><italic>Archives of Medical Research</italic></source><year>2002</year><volume>33</volume><issue>4</issue><fpage>351</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">12234524</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horwitz</surname><given-names>BJ</given-names></name><name><surname>Fisher</surname><given-names>RS</given-names></name></person-group><article-title>The irritable bowel syndrome</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2001</year><volume>344</volume><issue>24</issue><fpage>1846</fpage><lpage>1850</lpage><pub-id pub-id-type="pmid">11407347</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sandler</surname><given-names>RS</given-names></name><name><surname>Everhart</surname><given-names>JE</given-names></name><name><surname>Donowitz</surname><given-names>M</given-names></name><etal/></person-group><article-title>The burden of selected digestive diseases in the United States</article-title><source><italic>Gastroenterology</italic></source><year>2002</year><volume>122</volume><issue>5</issue><fpage>1500</fpage><lpage>1511</lpage><pub-id pub-id-type="pmid">11984534</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spiller</surname><given-names>R</given-names></name><name><surname>Campbell</surname><given-names>E</given-names></name></person-group><article-title>Post-infectious irritable bowel syndrome</article-title><source><italic>Current Opinion in Gastroenterology</italic></source><year>2006</year><volume>22</volume><issue>1</issue><fpage>13</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">16319671</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>EJ</given-names></name><name><surname>Boster</surname><given-names>DR</given-names></name><name><surname>Stapp</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Diarrhea etiology in a Children's Hospital Emergency Department: a prospective cohort study</article-title><source><italic>Clinical Infectious Diseases</italic></source><year>2006</year><volume>43</volume><issue>7</issue><fpage>807</fpage><lpage>813</lpage><pub-id pub-id-type="pmid">16941358</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>LR</given-names></name><name><surname>Manson</surname><given-names>RU</given-names></name><name><surname>Paule</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Detection of toxigenic <italic>Clostridium difficile</italic> in stool samples by real-time polymerase chain reaction for the diagnosis of <italic>C. difficile</italic>-associated diarrhea</article-title><source><italic>Clinical Infectious Diseases</italic></source><year>2007</year><volume>45</volume><issue>9</issue><fpage>1152</fpage><lpage>1160</lpage><pub-id pub-id-type="pmid">17918076</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marchesi</surname><given-names>J</given-names></name><name><surname>Shanahan</surname><given-names>F</given-names></name></person-group><article-title>The normal intestinal microbiota</article-title><source><italic>Current Opinion in Infectious Diseases</italic></source><year>2007</year><volume>20</volume><issue>5</issue><fpage>508</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">17762785</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gionchetti</surname><given-names>P</given-names></name><name><surname>Rizzello</surname><given-names>F</given-names></name><name><surname>Helwig</surname><given-names>U</given-names></name><etal/></person-group><article-title>Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial</article-title><source><italic>Gastroenterology</italic></source><year>2003</year><volume>124</volume><issue>5</issue><fpage>1202</fpage><lpage>1209</lpage><pub-id pub-id-type="pmid">12730861</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gionchetti</surname><given-names>P</given-names></name><name><surname>Rizzello</surname><given-names>F</given-names></name><name><surname>Venturi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial</article-title><source><italic>Gastroenterology</italic></source><year>2000</year><volume>119</volume><issue>2</issue><fpage>305</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">10930365</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shornikova</surname><given-names>A-V</given-names></name><name><surname>Casas</surname><given-names>IA</given-names></name><name><surname>Isolauri</surname><given-names>E</given-names></name><name><surname>Mykk&#x000e4;nen</surname><given-names>H</given-names></name><name><surname>Vesikari</surname><given-names>T</given-names></name></person-group><article-title>						<italic>Lactobacillus reuteri</italic> as a therapeutic agent in acute diarrhea in young children</article-title><source><italic>Journal of Pediatric Gastroenterology and Nutrition</italic></source><year>1997</year><volume>24</volume><issue>4</issue><fpage>399</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">9144122</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shornikova</surname><given-names>A-V</given-names></name><name><surname>Casas</surname><given-names>IA</given-names></name><name><surname>Mykk&#x000e4;nen</surname><given-names>H</given-names></name><name><surname>Salo</surname><given-names>E</given-names></name><name><surname>Vesikari</surname><given-names>T</given-names></name></person-group><article-title>Bacteriotherapy with <italic>Lactobacillus reuteri</italic> in rotavirus gastroenteritis</article-title><source><italic>Pediatric Infectious Disease Journal</italic></source><year>1997</year><volume>16</volume><issue>12</issue><fpage>1103</fpage><lpage>1107</lpage><pub-id pub-id-type="pmid">9427453</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weizman</surname><given-names>Z</given-names></name><name><surname>Asli</surname><given-names>G</given-names></name><name><surname>Alsheikh</surname><given-names>A</given-names></name></person-group><article-title>Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents</article-title><source><italic>Pediatrics</italic></source><year>2005</year><volume>115</volume><issue>1</issue><fpage>5</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15629974</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quigley</surname><given-names>EM</given-names></name></person-group><article-title>The efficacy of probiotics in IBS</article-title><source><italic>Journal of Clinical Gastroenterology</italic></source><year>2008</year><volume>42</volume><issue>supplement 2</issue><fpage>S85</fpage><lpage>S90</lpage><pub-id pub-id-type="pmid">18542036</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Metchnikoff</surname><given-names>E</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Mitchell</surname><given-names>PC</given-names></name></person-group><article-title>Lactic acid as inhibiting intestinal putrefaction</article-title><source><italic>The Prolongation of Life: Optimistic Studies</italic></source><year>1907</year><publisher-loc>London, UK</publisher-loc><publisher-name>Heinemann</publisher-name><fpage>161</fpage><lpage>183</lpage></citation></ref><ref id="B20"><label>20</label><citation citation-type="other"><collab>FAO/WHO</collab><year>2001</year><comment>paper presented at the Food and Agricultural Organization, Rome, Italy</comment></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corr</surname><given-names>SC</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Riedel</surname><given-names>CU</given-names></name><name><surname>O'Toole</surname><given-names>PW</given-names></name><name><surname>Hill</surname><given-names>C</given-names></name><name><surname>Gahan</surname><given-names>CGM</given-names></name></person-group><article-title>Bacteriocin production as a mechanism for the antiinfective activity of <italic>Lactobacillus salivarius</italic> UCC118</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2007</year><volume>104</volume><issue>18</issue><fpage>7617</fpage><lpage>7621</lpage><pub-id pub-id-type="pmid">17456596</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Selsted</surname><given-names>ME</given-names></name><name><surname>Ouellette</surname><given-names>AJ</given-names></name></person-group><article-title>Mammalian defensins in the antimicrobial immune response</article-title><source><italic>Nature Immunology</italic></source><year>2005</year><volume>6</volume><issue>6</issue><fpage>551</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">15908936</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wehkamp</surname><given-names>J</given-names></name><name><surname>Harder</surname><given-names>J</given-names></name><name><surname>Weichenthal</surname><given-names>M</given-names></name><etal/></person-group><article-title>NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal <italic>&#x003b1;</italic>-defensin expression</article-title><source><italic>Gut</italic></source><year>2004</year><volume>53</volume><issue>11</issue><fpage>1658</fpage><lpage>1664</lpage><pub-id pub-id-type="pmid">15479689</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wehkamp</surname><given-names>J</given-names></name><name><surname>Salzman</surname><given-names>NH</given-names></name><name><surname>Porter</surname><given-names>E</given-names></name><etal/></person-group><article-title>Reduced Paneth cell <italic>&#x003b1;</italic>-defensins in ileal Crohn's disease</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2005</year><volume>102</volume><issue>50</issue><fpage>18129</fpage><lpage>18134</lpage><pub-id pub-id-type="pmid">16330776</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Menendez</surname><given-names>A</given-names></name><name><surname>Finlay</surname><given-names>BB</given-names></name></person-group><article-title>Defensins in the immunology of bacterial infections</article-title><source><italic>Current Opinion in Immunology</italic></source><year>2007</year><volume>19</volume><issue>4</issue><fpage>385</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">17702560</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schlee</surname><given-names>M</given-names></name><name><surname>Wehkamp</surname><given-names>J</given-names></name><name><surname>Altenhoefer</surname><given-names>A</given-names></name><name><surname>Oelschlaeger</surname><given-names>TA</given-names></name><name><surname>Stange</surname><given-names>EF</given-names></name><name><surname>Fellermann</surname><given-names>K</given-names></name></person-group><article-title>Induction of human <italic>&#x003b2;</italic>-defensin 2 by the probiotic <italic>Escherichia coli</italic> Nissle 1917 is mediated through flagellin</article-title><source><italic>Infection and Immunity</italic></source><year>2007</year><volume>75</volume><issue>5</issue><fpage>2399</fpage><lpage>2407</lpage><pub-id pub-id-type="pmid">17283097</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wehkamp</surname><given-names>J</given-names></name><name><surname>Harder</surname><given-names>J</given-names></name><name><surname>Wehkamp</surname><given-names>K</given-names></name><etal/></person-group><article-title>NF-<italic>&#x003ba;</italic>B- and AP-1-mediated induction of human beta   defensin-2 in intestinal epithelial cells by <italic>Escherichia coli</italic> Nissle 1917: a novel effect of a probiotic bacterium</article-title><source><italic>Infection and Immunity</italic></source><year>2004</year><volume>72</volume><issue>10</issue><fpage>5750</fpage><lpage>5758</lpage><pub-id pub-id-type="pmid">15385474</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>CL</given-names></name><name><surname>Ouellette</surname><given-names>AJ</given-names></name><name><surname>Satchell</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Regulation of intestinal <italic>&#x003b1;</italic>-defensin activation by the metalloproteinase matrilysin in innate host defense</article-title><source><italic>Science</italic></source><year>1999</year><volume>286</volume><issue>5437</issue><fpage>113</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">10506557</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez-Boado</surname><given-names>YS</given-names></name><name><surname>Wilson</surname><given-names>CL</given-names></name><name><surname>Hooper</surname><given-names>LV</given-names></name><name><surname>Gordon</surname><given-names>JI</given-names></name><name><surname>Hultgren</surname><given-names>SJ</given-names></name><name><surname>Parks</surname><given-names>WC</given-names></name></person-group><article-title>Bacterial exposure induces and activates matrilysin in mucosal epithelial cells</article-title><source><italic>Journal of Cell Biology</italic></source><year>2000</year><volume>148</volume><issue>6</issue><fpage>1305</fpage><lpage>1315</lpage><pub-id pub-id-type="pmid">10725342</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson-Henry</surname><given-names>KC</given-names></name><name><surname>Hagen</surname><given-names>KE</given-names></name><name><surname>Gordonpour</surname><given-names>M</given-names></name><name><surname>Tompkins</surname><given-names>TA</given-names></name><name><surname>Sherman</surname><given-names>PM</given-names></name></person-group><article-title>Surface-layer protein extracts from <italic>Lactobacillus helveticus</italic> inhibit enterohaemorrhagic <italic>Escherichia coli</italic> O157:H7 adhesion to epithelial cells</article-title><source><italic>Cellular Microbiology</italic></source><year>2007</year><volume>9</volume><issue>2</issue><fpage>356</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">16925785</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spurbeck</surname><given-names>RR</given-names></name><name><surname>Arvidson</surname><given-names>CG</given-names></name></person-group><article-title>Inhibition of <italic>Neisseria gonorrhoeae</italic> epithelial cell interactions by vaginal <italic>Lactobacillus</italic> species</article-title><source><italic>Infection and Immunity</italic></source><year>2008</year><volume>76</volume><issue>7</issue><fpage>3124</fpage><lpage>3130</lpage><pub-id pub-id-type="pmid">18411284</pub-id></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Medellin-Pe&#x000f1;a</surname><given-names>MJ</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Johnson</surname><given-names>R</given-names></name><name><surname>Anand</surname><given-names>S</given-names></name><name><surname>Griffiths</surname><given-names>MW</given-names></name></person-group><article-title>Probiotics affect virulence-related gene expression in <italic>Escherichia coli</italic> O157:H7</article-title><source><italic>Applied and Environmental Microbiology</italic></source><year>2007</year><volume>73</volume><issue>13</issue><fpage>4259</fpage><lpage>4267</lpage><pub-id pub-id-type="pmid">17496132</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname><given-names>HR</given-names></name><name><surname>Fr&#x000f8;ki&#x000e6;r</surname><given-names>H</given-names></name><name><surname>Pestka</surname><given-names>JJ</given-names></name></person-group><article-title>Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells</article-title><source><italic>The Journal of Immunology</italic></source><year>2002</year><volume>168</volume><issue>1</issue><fpage>171</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">11751960</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YP</given-names></name><name><surname>Thibodeaux</surname><given-names>CH</given-names></name><name><surname>Pe&#x000f1;a</surname><given-names>JA</given-names></name><name><surname>Ferry</surname><given-names>GD</given-names></name><name><surname>Versalovic</surname><given-names>J</given-names></name></person-group><article-title>Probiotic <italic>Lactobacillus reuteri</italic> suppress proinflammatory cytokines via c-Jun</article-title><source><italic>Inflammatory Bowel Diseases</italic></source><year>2008</year><volume>14</volume><issue>8</issue><fpage>1068</fpage><lpage>1083</lpage><pub-id pub-id-type="pmid">18425802</pub-id></citation></ref><ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miettinen</surname><given-names>M</given-names></name><name><surname>Lehtonen</surname><given-names>A</given-names></name><name><surname>Julkunen</surname><given-names>I</given-names></name><name><surname>Matikainen</surname><given-names>S</given-names></name></person-group><article-title>Lactobacilli and streptococci activate NF-<italic>&#x003ba;</italic>B and STAT signaling pathways in human macrophages</article-title><source><italic>The Journal of Immunology</italic></source><year>2000</year><volume>164</volume><issue>7</issue><fpage>3733</fpage><lpage>3740</lpage><pub-id pub-id-type="pmid">10725732</pub-id></citation></ref><ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname><given-names>C</given-names></name><name><surname>Kosters</surname><given-names>A</given-names></name><name><surname>Sethi</surname><given-names>G</given-names></name><name><surname>Kunnumakkara</surname><given-names>AB</given-names></name><name><surname>Aggarwal</surname><given-names>BB</given-names></name><name><surname>Versalovic</surname><given-names>J</given-names></name></person-group><article-title>Probiotic <italic>Lactobacillus reuteri</italic> promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-<italic>&#x003ba;</italic>B and MAPK signalling</article-title><source><italic>Cellular Microbiology</italic></source><year>2008</year><volume>10</volume><issue>7</issue><fpage>1442</fpage><lpage>1452</lpage><pub-id pub-id-type="pmid">18331465</pub-id></citation></ref><ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petrof</surname><given-names>EO</given-names></name><name><surname>Kojima</surname><given-names>K</given-names></name><name><surname>Ropeleski</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Probiotics inhibit nuclear factor-<italic>&#x003ba;</italic>B and induce heat shock proteins in colonic epithelial cells through proteasome inhibition</article-title><source><italic>Gastroenterology</italic></source><year>2004</year><volume>127</volume><issue>5</issue><fpage>1474</fpage><lpage>1487</lpage><pub-id pub-id-type="pmid">15521016</pub-id></citation></ref><ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guttman</surname><given-names>JA</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wickham</surname><given-names>ME</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Vogl</surname><given-names>AW</given-names></name><name><surname>Finlay</surname><given-names>BB</given-names></name></person-group><article-title>Attaching and effacing pathogen-induced tight junction disruption in vivo</article-title><source><italic>Cellular Microbiology</italic></source><year>2006</year><volume>8</volume><issue>4</issue><fpage>634</fpage><lpage>645</lpage><pub-id pub-id-type="pmid">16548889</pub-id></citation></ref><ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hecht</surname><given-names>G</given-names></name></person-group><article-title>Microbes and microbial toxins: paradigms for microbial-mucosal interactions. VII. Enteropathogenic <italic>Escherichia coli</italic>: physiological alterations from an extracellular position</article-title><source><italic>American Journal of Physiology Gastrointestinal and Liver Physiology</italic></source><year>2001</year><volume>281</volume><issue>1</issue><fpage>G1</fpage><lpage>G7</lpage><pub-id pub-id-type="pmid">11408249</pub-id></citation></ref><ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson-Henry</surname><given-names>KC</given-names></name><name><surname>Donato</surname><given-names>KA</given-names></name><name><surname>Shen-Tu</surname><given-names>G</given-names></name><name><surname>Gordanpour</surname><given-names>M</given-names></name><name><surname>Sherman</surname><given-names>PM</given-names></name></person-group><article-title>						<italic>Lactobacillus rhamnosus</italic> strain GG prevents enterohemorrhagic <italic>Escherichia coli</italic> O157:H7-induced changes in epithelial barrier function</article-title><source><italic>Infection and Immunity</italic></source><year>2008</year><volume>76</volume><issue>4</issue><fpage>1340</fpage><lpage>1348</lpage><pub-id pub-id-type="pmid">18227169</pub-id></citation></ref><ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klingberg</surname><given-names>TD</given-names></name><name><surname>Pedersen</surname><given-names>MH</given-names></name><name><surname>Cencic</surname><given-names>A</given-names></name><name><surname>Budde</surname><given-names>BB</given-names></name></person-group><article-title>Application of measurements of transepithelial electrical resistance of intestinal epithelial cell monolayers to evaluate probiotic activity</article-title><source><italic>Applied and Environmental Microbiology</italic></source><year>2005</year><volume>71</volume><issue>11</issue><fpage>7528</fpage><lpage>7530</lpage><pub-id pub-id-type="pmid">16269795</pub-id></citation></ref><ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steidler</surname><given-names>L</given-names></name><name><surname>Hans</surname><given-names>W</given-names></name><name><surname>Schotte</surname><given-names>L</given-names></name><etal/></person-group><article-title>Treatment of murine colitis by <italic>Lactococcus lactis</italic> secreting interleukin-10</article-title><source><italic>Science</italic></source><year>2000</year><volume>289</volume><issue>5483</issue><fpage>1352</fpage><lpage>1355</lpage><pub-id pub-id-type="pmid">10958782</pub-id></citation></ref><ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pe&#x000f1;a</surname><given-names>JA</given-names></name><name><surname>Li</surname><given-names>SY</given-names></name><name><surname>Wilson</surname><given-names>PH</given-names></name><name><surname>Thibodeau</surname><given-names>SA</given-names></name><name><surname>Szary</surname><given-names>AJ</given-names></name><name><surname>Versalovic</surname><given-names>J</given-names></name></person-group><article-title>Genotypic and phenotypic studies of murine intestinal lactobacilli: species differences in mice with and without colitis</article-title><source><italic>Applied and Environmental Microbiology</italic></source><year>2004</year><volume>70</volume><issue>1</issue><fpage>558</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">14711688</pub-id></citation></ref><ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wall</surname><given-names>T</given-names></name><name><surname>B&#x000e5;th</surname><given-names>K</given-names></name><name><surname>Britton</surname><given-names>RA</given-names></name><name><surname>Jonsson</surname><given-names>H</given-names></name><name><surname>Versalovic</surname><given-names>J</given-names></name><name><surname>Roos</surname><given-names>S</given-names></name></person-group><article-title>The early response to acid shock in <italic>Lactobacillus reuteri</italic> involves the ClpL chaperone and a putative cell wall-altering esterase</article-title><source><italic>Applied and Environmental Microbiology</italic></source><year>2007</year><volume>73</volume><issue>12</issue><fpage>3924</fpage><lpage>3935</lpage><pub-id pub-id-type="pmid">17449683</pub-id></citation></ref><ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whitehead</surname><given-names>K</given-names></name><name><surname>Versalovic</surname><given-names>J</given-names></name><name><surname>Roos</surname><given-names>S</given-names></name><name><surname>Britton</surname><given-names>RA</given-names></name></person-group><article-title>Genomic and genetic characterization of the bile stress response of probiotic <italic>Lactobacillus reuteri</italic> ATCC 55730</article-title><source><italic>Applied and Environmental Microbiology</italic></source><year>2008</year><volume>74</volume><issue>6</issue><fpage>1812</fpage><lpage>1819</lpage><pub-id pub-id-type="pmid">18245259</pub-id></citation></ref><ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>G</given-names></name></person-group><article-title>Probiotics in the treatment of diarrheal diseases</article-title><source><italic>Current Infectious Disease Reports</italic></source><year>2000</year><volume>2</volume><issue>1</issue><fpage>78</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">11095842</pub-id></citation></ref><ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oberhelman</surname><given-names>RA</given-names></name><name><surname>Gilman</surname><given-names>RH</given-names></name><name><surname>Sheen</surname><given-names>P</given-names></name><etal/></person-group><article-title>A placebo-controlled trial of <italic>Lactobacillus</italic> GG to prevent diarrhea in undernourished Peruvian children</article-title><source><italic>The Journal of Pediatrics</italic></source><year>1999</year><volume>134</volume><issue>1</issue><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">9880443</pub-id></citation></ref><ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pedone</surname><given-names>CA</given-names></name><name><surname>Arnaud</surname><given-names>CC</given-names></name><name><surname>Postaire</surname><given-names>ER</given-names></name><name><surname>Bouley</surname><given-names>CF</given-names></name><name><surname>Reinert</surname><given-names>P</given-names></name></person-group><article-title>Multicentric study of the effect of milk fermented by <italic>Lactobacillus casei</italic> on the incidence of diarrhoea</article-title><source><italic>International Journal of Clinical Practice</italic></source><year>2000</year><volume>54</volume><issue>9</issue><fpage>568</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">11220983</pub-id></citation></ref><ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saavedra</surname><given-names>JM</given-names></name><name><surname>Bauman</surname><given-names>NA</given-names></name><name><surname>Oung</surname><given-names>I</given-names></name><name><surname>Perman</surname><given-names>JA</given-names></name><name><surname>Yolken</surname><given-names>RH</given-names></name></person-group><article-title>Feeding of <italic>Bifidobacterium bifidum</italic> and <italic>Streptococcus thermophilus</italic> to infants in hospital for prevention of diarrhoea and shedding of rotavirus</article-title><source><italic>The Lancet</italic></source><year>1994</year><volume>344</volume><issue>8929</issue><fpage>1046</fpage><lpage>1049</lpage></citation></ref><ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szajewska</surname><given-names>H</given-names></name><name><surname>Mrukowicz</surname><given-names>JZ</given-names></name></person-group><article-title>Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials</article-title><source><italic>Journal of Pediatric Gastroenterology and Nutrition</italic></source><year>2001</year><volume>33</volume><issue>4</issue><supplement>supplement 2</supplement><fpage>S17</fpage><lpage>S25</lpage><pub-id pub-id-type="pmid">11698781</pub-id></citation></ref><ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arvola</surname><given-names>T</given-names></name><name><surname>Laiho</surname><given-names>K</given-names></name><name><surname>Torkkeli</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prophylactic <italic>Lactobacillus GG</italic> reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study</article-title><source><italic>Pediatrics</italic></source><year>1999</year><volume>104</volume><issue>5, article e64</issue><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">10390252</pub-id></citation></ref><ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corr&#x000ea;a</surname><given-names>NBO</given-names></name><name><surname>P&#x000e9;ret Filho</surname><given-names>LA</given-names></name><name><surname>Penna</surname><given-names>FJ</given-names></name><name><surname>Lima</surname><given-names>FMLS</given-names></name><name><surname>Nicoli</surname><given-names>JR</given-names></name></person-group><article-title>A randomized formula controlled trial of <italic>Bifidobacterium lactis</italic> and <italic>Streptococcus thermophilus</italic> for prevention of antibiotic-associated diarrhea in infants</article-title><source><italic>Journal of Clinical Gastroenterology</italic></source><year>2005</year><volume>39</volume><issue>5</issue><fpage>385</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">15815206</pub-id></citation></ref><ref id="B53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jirapinyo</surname><given-names>P</given-names></name><name><surname>Thamonsiri</surname><given-names>N</given-names></name><name><surname>Densupsoontorn</surname><given-names>N</given-names></name><name><surname>Wongarn</surname><given-names>R</given-names></name></person-group><article-title>Prevention of antibiotic-associated diarrhea in infants by probiotics</article-title><source><italic>Journal of the Medical Association of Thailand</italic></source><year>2002</year><volume>85</volume><issue>supplement 2</issue><fpage>S739</fpage><lpage>S742</lpage><pub-id pub-id-type="pmid">12403254</pub-id></citation></ref><ref id="B54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vanderhoof</surname><given-names>JA</given-names></name><name><surname>Whitney</surname><given-names>DB</given-names></name><name><surname>Antonson</surname><given-names>DL</given-names></name><name><surname>Hanner</surname><given-names>TL</given-names></name><name><surname>Lupo</surname><given-names>JV</given-names></name><name><surname>Young</surname><given-names>RJ</given-names></name></person-group><article-title>						<italic>Lactobacillus GG</italic> in the prevention of antibiotic-associated diarrhea in children</article-title><source><italic>The Journal of Pediatrics</italic></source><year>1999</year><volume>135</volume><issue>5</issue><fpage>564</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">10547243</pub-id></citation></ref><ref id="B55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szajewska</surname><given-names>H</given-names></name><name><surname>Setty</surname><given-names>M</given-names></name><name><surname>Mrukowicz</surname><given-names>J</given-names></name><name><surname>Guandalini</surname><given-names>S</given-names></name></person-group><article-title>Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy</article-title><source><italic>Journal of Pediatric Gastroenterology and Nutrition</italic></source><year>2006</year><volume>42</volume><issue>5</issue><fpage>454</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">16707966</pub-id></citation></ref><ref id="B56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>SJ</given-names></name><name><surname>Okoko</surname><given-names>B</given-names></name><name><surname>Martinez</surname><given-names>E</given-names></name><name><surname>Gregorio</surname><given-names>G</given-names></name><name><surname>Dans</surname><given-names>LF</given-names></name></person-group><article-title>Probiotics for treating infectious diarrhoea</article-title><source><italic>Cochrane Database of Systematic Reviews</italic></source><year>2004</year><issue>4</issue><comment>Article ID CD003048.</comment></citation></ref><ref id="B57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guandalini</surname><given-names>S</given-names></name><name><surname>Pensabene</surname><given-names>L</given-names></name><name><surname>Zikri</surname><given-names>MA</given-names></name><etal/></person-group><article-title>						<italic>Lactobacillus GG</italic> administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial</article-title><source><italic>Journal of Pediatric Gastroenterology and Nutrition</italic></source><year>2000</year><volume>30</volume><issue>1</issue><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">10630440</pub-id></citation></ref><ref id="B58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kyne</surname><given-names>L</given-names></name><name><surname>Hamel</surname><given-names>MB</given-names></name><name><surname>Polavaram</surname><given-names>R</given-names></name><name><surname>Kelly</surname><given-names>CP</given-names></name></person-group><article-title>Health care costs and mortality associated with nosocomial diarrhea due to <italic>Clostridium difficile</italic></article-title><source><italic>Clinical Infectious Diseases</italic></source><year>2002</year><volume>34</volume><issue>3</issue><fpage>346</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">11774082</pub-id></citation></ref><ref id="B59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laffan</surname><given-names>AM</given-names></name><name><surname>Bellantoni</surname><given-names>MF</given-names></name><name><surname>Greenough</surname><given-names>WB</given-names><suffix>III</suffix></name><name><surname>Zenilman</surname><given-names>JM</given-names></name></person-group><article-title>Burden of <italic>Clostridium difficile</italic>-associated diarrhea in a long-term care facility</article-title><source><italic>Journal of the American Geriatrics Society</italic></source><year>2006</year><volume>54</volume><issue>7</issue><fpage>1068</fpage><lpage>1073</lpage><pub-id pub-id-type="pmid">16866677</pub-id></citation></ref><ref id="B60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilkins</surname><given-names>TD</given-names></name><name><surname>Lyerly</surname><given-names>DM</given-names></name></person-group><article-title>						<italic>Clostridium difficile</italic> testing: after 20 years, still challenging</article-title><source><italic>Journal of Clinical Microbiology</italic></source><year>2003</year><volume>41</volume><issue>2</issue><fpage>531</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">12574241</pub-id></citation></ref><ref id="B61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aslam</surname><given-names>S</given-names></name><name><surname>Hamill</surname><given-names>RJ</given-names></name><name><surname>Musher</surname><given-names>DM</given-names></name></person-group><article-title>Treatment of <italic>Clostridium difficile</italic>-associated disease: old therapies and new strategies</article-title><source><italic>Lancet Infectious Diseases</italic></source><year>2005</year><volume>5</volume><issue>9</issue><fpage>549</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">16122678</pub-id></citation></ref><ref id="B62"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartlett</surname><given-names>JG</given-names></name><name><surname>Chang</surname><given-names>TW</given-names></name><name><surname>Moon</surname><given-names>N</given-names></name><name><surname>Onderdonk</surname><given-names>AB</given-names></name></person-group><article-title>Antibiotic-induced lethal enterocolitis in hamsters: studies with eleven agents and evidence to support the pathogenic role of toxin-producing <italic>clostridia</italic></article-title><source><italic>American Journal of Veterinary Research</italic></source><year>1978</year><volume>39</volume><issue>9</issue><fpage>1525</fpage><lpage>1530</lpage><pub-id pub-id-type="pmid">697162</pub-id></citation></ref><ref id="B63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuijper</surname><given-names>EJ</given-names></name><name><surname>van Dissel</surname><given-names>JT</given-names></name><name><surname>Wilcox</surname><given-names>MH</given-names></name></person-group><article-title>						<italic>Clostridium difficile</italic>: changing epidemiology and new treatment options</article-title><source><italic>Current Opinion in Infectious Diseases</italic></source><year>2007</year><volume>20</volume><issue>4</issue><fpage>376</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">17609596</pub-id></citation></ref><ref id="B64"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>JY</given-names></name><name><surname>Antonopoulos</surname><given-names>DA</given-names></name><name><surname>Kalra</surname><given-names>A</given-names></name><etal/></person-group><article-title>Decreased diversity of the fecal microbiome in recurrent <italic>Clostridium difficile</italic>-associated diarrhea</article-title><source><italic>The Journal of Infectious Diseases</italic></source><year>2008</year><volume>197</volume><issue>3</issue><fpage>435</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">18199029</pub-id></citation></ref><ref id="B65"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pillai</surname><given-names>A</given-names></name><name><surname>Nelson</surname><given-names>RL</given-names></name></person-group><article-title>Probiotics for treatment of <italic>Clostridium difficile</italic>-associated colitis in adults</article-title><source><italic>Cochrane Database of Systematic Reviews</italic></source><year>2008</year><issue>1</issue><comment>Article ID CD004611.</comment></citation></ref><ref id="B66"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sambol</surname><given-names>SP</given-names></name><name><surname>Merrigan</surname><given-names>MM</given-names></name><name><surname>Tang</surname><given-names>JK</given-names></name><name><surname>Johnson</surname><given-names>S</given-names></name><name><surname>Gerding</surname><given-names>DN</given-names></name></person-group><article-title>Colonization for the prevention of <italic>Clostridium difficile</italic> disease in hamsters</article-title><source><italic>The Journal of Infectious Diseases</italic></source><year>2002</year><volume>186</volume><issue>12</issue><fpage>1781</fpage><lpage>1789</lpage><pub-id pub-id-type="pmid">12447764</pub-id></citation></ref><ref id="B67"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sorg</surname><given-names>JA</given-names></name><name><surname>Sonenshein</surname><given-names>AL</given-names></name></person-group><article-title>Bile salts and glycine as co-germinants for <italic>Clostridium difficile</italic> spores</article-title><source><italic>Journal of Bacteriology</italic></source><year>2008</year><volume>190</volume><issue>7</issue><fpage>2505</fpage><lpage>2512</lpage><pub-id pub-id-type="pmid">18245298</pub-id></citation></ref><ref id="B68"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riley</surname><given-names>LW</given-names></name><name><surname>Remis</surname><given-names>RS</given-names></name><name><surname>Helgerson</surname><given-names>SD</given-names></name><etal/></person-group><article-title>Hemmorhagic colitis associated with a rare <italic>Escherichia coli</italic> serotype</article-title><source><italic>The New England Journal of Medicine</italic></source><year>1983</year><volume>308</volume><issue>12</issue><fpage>681</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">6338386</pub-id></citation></ref><ref id="B69"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donnenberg</surname><given-names>MS</given-names></name><name><surname>Whittam</surname><given-names>TS</given-names></name></person-group><article-title>Pathogenesis and evolution of virulence in enteropathogenic and enterohemorrhagic <italic>Escherichia coli</italic></article-title><source><italic>The Journal of Clinical Investigation</italic></source><year>2001</year><volume>107</volume><issue>5</issue><fpage>539</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">11238553</pub-id></citation></ref><ref id="B70"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaper</surname><given-names>JB</given-names></name><name><surname>Nataro</surname><given-names>JP</given-names></name><name><surname>Mobley</surname><given-names>HLT</given-names></name></person-group><article-title>Pathogenic <italic>Escherichia coli</italic></article-title><source><italic>Nature Reviews Microbiology</italic></source><year>2004</year><volume>2</volume><issue>2</issue><fpage>123</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">15040260</pub-id></citation></ref><ref id="B71"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wick</surname><given-names>LM</given-names></name><name><surname>Qi</surname><given-names>W</given-names></name><name><surname>Lacher</surname><given-names>DW</given-names></name><name><surname>Whittam</surname><given-names>TS</given-names></name></person-group><article-title>Evolution of genomic content in the stepwise emergence of <italic>Escherichia coli</italic> O157:H7</article-title><source><italic>Journal of Bacteriology</italic></source><year>2005</year><volume>187</volume><issue>5</issue><fpage>1783</fpage><lpage>1791</lpage><pub-id pub-id-type="pmid">15716450</pub-id></citation></ref><ref id="B72"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sandvig</surname><given-names>K</given-names></name></person-group><article-title>Shiga toxins</article-title><source><italic>Toxicon</italic></source><year>2001</year><volume>39</volume><issue>11</issue><fpage>1629</fpage><lpage>1635</lpage><pub-id pub-id-type="pmid">11595626</pub-id></citation></ref><ref id="B73"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eaton</surname><given-names>KA</given-names></name><name><surname>Friedman</surname><given-names>DI</given-names></name><name><surname>Francis</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>Pathogenesis of renal disease due to enterohemorrhagic <italic>Escherichia coli</italic> in germ-free mice</article-title><source><italic>Infection and Immunity</italic></source><year>2008</year><volume>76</volume><issue>7</issue><fpage>3054</fpage><lpage>3063</lpage><pub-id pub-id-type="pmid">18443087</pub-id></citation></ref><ref id="B74"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keepers</surname><given-names>TR</given-names></name><name><surname>Psotka</surname><given-names>MA</given-names></name><name><surname>Gross</surname><given-names>LK</given-names></name><name><surname>Obrig</surname><given-names>TG</given-names></name></person-group><article-title>A murine model of HUS: shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease</article-title><source><italic>Journal of the American Society of Nephrology</italic></source><year>2006</year><volume>17</volume><issue>12</issue><fpage>3404</fpage><lpage>3414</lpage><pub-id pub-id-type="pmid">17082244</pub-id></citation></ref><ref id="B75"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tarr</surname><given-names>PI</given-names></name><name><surname>Gordon</surname><given-names>CA</given-names></name><name><surname>Chandler</surname><given-names>WL</given-names></name></person-group><article-title>Shiga-toxin-producing <italic>Escherichia coli</italic> and haemolytic uraemic syndrome</article-title><source><italic>The Lancet</italic></source><year>2005</year><volume>365</volume><issue>9464</issue><fpage>1073</fpage><lpage>1086</lpage></citation></ref><ref id="B76"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paton</surname><given-names>AW</given-names></name><name><surname>Morona</surname><given-names>R</given-names></name><name><surname>Paton</surname><given-names>JC</given-names></name></person-group><article-title>Neutralization of Shiga toxins Stx1, Stx2c, and Stx2e by recombinant bacteria expressing mimics of globotriose and globotetraose</article-title><source><italic>Infection and Immunity</italic></source><year>2001</year><volume>69</volume><issue>3</issue><fpage>1967</fpage><lpage>1970</lpage><pub-id pub-id-type="pmid">11179385</pub-id></citation></ref><ref id="B77"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paton</surname><given-names>AW</given-names></name><name><surname>Morona</surname><given-names>R</given-names></name><name><surname>Paton</surname><given-names>JC</given-names></name></person-group><article-title>Designer probiotics for prevention of enteric infections</article-title><source><italic>Nature Reviews Microbiology</italic></source><year>2006</year><volume>4</volume><issue>3</issue><fpage>193</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">16462752</pub-id></citation></ref><ref id="B78"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pinyon</surname><given-names>RA</given-names></name><name><surname>Paton</surname><given-names>JC</given-names></name><name><surname>Paton</surname><given-names>AW</given-names></name><name><surname>Bottan</surname><given-names>JA</given-names></name><name><surname>Morona</surname><given-names>R</given-names></name></person-group><article-title>Refinement of a therapeutic Shiga toxin-binding probiotic for human trials</article-title><source><italic>The Journal of Infectious Diseases</italic></source><year>2004</year><volume>189</volume><issue>9</issue><fpage>1547</fpage><lpage>1555</lpage><pub-id pub-id-type="pmid">15116289</pub-id></citation></ref><ref id="B79"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paton</surname><given-names>JC</given-names></name><name><surname>Rogers</surname><given-names>TJ</given-names></name><name><surname>Morona</surname><given-names>R</given-names></name><name><surname>Paton</surname><given-names>AW</given-names></name></person-group><article-title>Oral administration of formaldehyde-killed recombinant bacteria expressing a mimic of the Shiga toxin receptor protects mice from fatal challenge with shiga-toxigenic <italic>Escherichia coli</italic></article-title><source><italic>Infection and Immunity</italic></source><year>2001</year><volume>69</volume><issue>3</issue><fpage>1389</fpage><lpage>1393</lpage><pub-id pub-id-type="pmid">11179303</pub-id></citation></ref><ref id="B80"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waldor</surname><given-names>MK</given-names></name><name><surname>Friedman</surname><given-names>DI</given-names></name></person-group><article-title>Phage regulatory circuits and virulence gene expression</article-title><source><italic>Current Opinion in Microbiology</italic></source><year>2005</year><volume>8</volume><issue>4</issue><fpage>459</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">15979389</pub-id></citation></ref><ref id="B81"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vallance</surname><given-names>BA</given-names></name><name><surname>Chan</surname><given-names>C</given-names></name><name><surname>Robertson</surname><given-names>ML</given-names></name><name><surname>Finlay</surname><given-names>BB</given-names></name></person-group><article-title>Enteropathogenic and enterohemorrhagic <italic>Escherichia coli</italic> infections: emerging themes in pathogenesis and prevention</article-title><source><italic>Canadian Journal of Gastroenterology</italic></source><year>2002</year><volume>16</volume><issue>11</issue><fpage>771</fpage><lpage>778</lpage><pub-id pub-id-type="pmid">12464970</pub-id></citation></ref><ref id="B82"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muza-Moons</surname><given-names>MM</given-names></name><name><surname>Schneeberger</surname><given-names>EE</given-names></name><name><surname>Hecht</surname><given-names>GA</given-names></name></person-group><article-title>Enteropathogenic <italic>Escherichia coli</italic> infection leads to appearance of aberrant tight junctions strands in the lateral membrane of intestinal epithelial cells</article-title><source><italic>Cellular Microbiology</italic></source><year>2004</year><volume>6</volume><issue>8</issue><fpage>783</fpage><lpage>793</lpage><pub-id pub-id-type="pmid">15236645</pub-id></citation></ref><ref id="B83"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shifflett</surname><given-names>DE</given-names></name><name><surname>Clayburgh</surname><given-names>DR</given-names></name><name><surname>Koutsouris</surname><given-names>A</given-names></name><name><surname>Turner</surname><given-names>JR</given-names></name><name><surname>Hecht</surname><given-names>GA</given-names></name></person-group><article-title>Enteropathogenic <italic>E. coli</italic> disrupts tight junction barrier function and structure in vivo</article-title><source><italic>Laboratory Investigation</italic></source><year>2005</year><volume>85</volume><issue>10</issue><fpage>1308</fpage><lpage>1324</lpage><pub-id pub-id-type="pmid">16127426</pub-id></citation></ref><ref id="B84"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pant</surname><given-names>N</given-names></name><name><surname>Marcotte</surname><given-names>H</given-names></name><name><surname>Br&#x000fc;ssow</surname><given-names>H</given-names></name><name><surname>Svensson</surname><given-names>L</given-names></name><name><surname>Hammarstr&#x000f6;m</surname><given-names>L</given-names></name></person-group><article-title>Effective prophylaxis against rotavirus diarrhea using a combination of <italic>Lactobacillus rhamnosus</italic> GG and antibodies</article-title><source><italic>BMC Microbiology</italic></source><year>2007</year><volume>7, article 86</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17233889</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1" position="float"><label>Figure 1</label><caption><p>					<italic>Probiotics and Beneficial Effects in the Intestine</italic>. Depiction of the interactions between beneficialbacteria (left side), their secreted factors, pathogens, and the intestinalmucosa (right side). Potential beneficial effects of probiotics are listed. Only two host cell types are shown, intestinal epithelial cells and macrophagesalthough other cell types including dendritic cells, lymphocytes,myofibroblasts, and neutrophils comprise the intestinal mucosa. The arrowsindicate the release and possible distribution of secreted factors derived fromprobiotics.</p></caption><graphic xlink:href="IPID2008-290769.001"/></fig></floats-wrap></article>